Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in this application:

- 1. (currently amended) A stabilized drug delivery system for proton pump inhibitors which comprises comprising a benzimidazole compound or their salts a salt thereof and a pharmaceutically acceptable excipients excipient in powder form, which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.
- 2. (currently amended) The drug delivery system as claimed in claim 1, wherein the said salts of Rabeprazole may be salt is in the form of alkaline metal salts salt or alkaline earth metal salts salt.
- 3. (currently amended) The drug delivery system as claimed in claims 1 and claim 2, wherein the said alkaline metal salts may be is sodium or potassium.
- 4. (currently amended) The drug delivery system as claimed in claims 1 and claim 2, wherein the said alkaline earth metal salts may be is calcium or magnesium.
- 5. (currently amended) The drug delivery system as claimed in claim 1, wherein the said system comprises Rabeprazole sodium, mannitol, alkaline compounds and water for injection.

- 6. (currently amended) The drug delivery system as claimed in claim 1, wherein the said system is preferably in the form of a stabilized lyophilized injection.
- 7. (currently amended) The drug delivery system as claimed in claim 5, wherein the said alkaline compound is sodium hydroxide.
- 8. (currently amended) The drug delivery system as claimed in elaims claim 1 to 7, wherein the pH of the said system is between 9 11.
- 9. (currently amended) The drug delivery system as claimed in claims claim 1 to 8, wherein the said Rabeprazole benzimidazole compound in the said reconstitutable powder form is present in the range of 8% to 77%, preferably 19 62% by weight of the total composition.
- 10. (currently amended) The drug delivery system as claimed in claims claim 1 to 8, wherein the said Mannitol excipient in the said reconstitutable powder form is present in the range of 19% to 88%, preferably 19-62% by weight of the total composition.
- 11. (delete)
- 12. (currently amended) The drug delivery system for proton pump inhibitor prepared by process as claimed in claim 11 18.

13-14. (delete)

Please add the following claims:

- 15. (new) The drug delivery system as claimed in claim 1, wherein the benzimidazole compound or the salt thereof is Rabeprazole or its salt.
- 16. (new) The drug delivery system as claimed in claim 9, wherein the said benzimidazole compound is present in the range of 19 62% by weight of the total composition.
- 17. (new) The drug delivery system as claimed in claim 10, wherein the said excipient is present in the range of 30% 88% by weight of the total composition.
- 18. (new) A process for preparation of the said drug delivery system comprising the steps of
- (a) dissolving sodium hydroxide in Water For Injection to adjust the pH above 12.0 to form a solution;
- (b) adding Mannitol and Rabeprazole sodium to said solution while maintaining the pH of the said solution;
 - (c) making up the volume with water for injection;
 - (d) filtering the said solution aseptically through 0.22μ filter paper;
 - (e) filling the said filtered solution in previously sterilized 10ml vials;
- (f) maintaining the temperature of the injectable solution at 10°C±2°C throughout the process;

- (g) loading the vials into lyophilizer after partial lounging; and
- (f) lyophilizing the solution to obtain a powder form the drug delivery system which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.